vida: extract claims from 2026-04-28-glp1-managed-access-operating-systems-payer-infrastructure

- Source: inbox/queue/2026-04-28-glp1-managed-access-operating-systems-payer-infrastructure.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-behavioral-mandate-rate-tripled-2024-2025-signaling-managed-access-infrastructure-shift.md

@@ -11,9 +11,16 @@ sourced_from: health/2026-04-28-phti-employer-glp1-coverage-behavioral-mandate-2
 scope: structural
 sourcer: Peterson Health Technology Institute
 supports: ["glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024"]
-related: ["glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support"]
+related: ["glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary"]
 ---
 
 # GLP-1 behavioral support mandates tripled in one year (10% to 34%) signaling structural shift from drug-only formulary to managed-access operating systems
 
 PHTI's December 2025 employer survey found that 34% of firms covering GLP-1s now require dietitian, case management, therapy, or lifestyle participation as a coverage condition, up from 10% the prior year—a 3.4x increase in 12 months. This is not incremental adoption but structural acceleration. Three major payers have operationalized this shift: Evernorth EncircleRx (9M lives, $200M saved since 2024), Optum Rx Weight Engage (coaching + specialist navigation), and UHC Total Weight Support (mandates Real Appeal Rx or WeightWatchers as coverage prerequisite). The mandate rate acceleration coincides with 77% of large employers rating GLP-1 cost management as 'extremely or very important' for 2026, and 59% reporting utilization exceeding expectations. The shift is driven by economic necessity: 36.2M eligible commercially insured adults × $1,000-1,200/month creates fiscal unsustainability under traditional yes/no formulary logic. Payers are building what PHTI calls 'managed-access operating systems' covering population qualification, channel routing, behavioral gates, subsidy levels, and discontinuation rules. This is infrastructure, not incremental policy adjustment.
+
+
+## Supporting Evidence
+
+**Source:** on/healthcare.tech analysis, UHC Total Weight Support structure
+
+43% of 5,000+ employee firms now cover GLP-1s for weight loss (up from 28% in 2024), with 34% requiring behavioral participation as coverage condition (up from 10%). UHC Total Weight Support requires coaching engagement (Real Appeal Rx or WeightWatchers) as coverage prerequisite. This confirms the behavioral mandate trend with specific payer implementation examples.

domains/health/glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024.md

@@ -11,7 +11,7 @@ sourced_from: health/2026-04-23-icer-glp1-affordable-access-2025.md
 scope: structural
 sourcer: ICER
 supports: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "medicaid-glp1-coverage-reversing-through-state-budget-pressure"]
-related: ["glp-1-receptor-agonists-are-the-largest-therapeutic-category-launch-in-pharmaceutical-history-but-their-chronic-use-model-makes-the-net-cost-impact-inflationary-through-2035", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024"]
+related: ["glp-1-receptor-agonists-are-the-largest-therapeutic-category-launch-in-pharmaceutical-history-but-their-chronic-use-model-makes-the-net-cost-impact-inflationary-through-2035", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary"]
 ---
 
 # GLP-1 obesity coverage creates acute payer fiscal crisis with employer plans experiencing >10x PMPM cost increases in 2023-2024 and major insurers reporting operating losses driven primarily by GLP-1 expenditures
@@ -31,3 +31,10 @@ Employer response to GLP-1 cost pressure includes cost management strategies: st
 **Source:** on/healthcare.tech, Evernorth EncircleRx operational data
 
 Evernorth EncircleRx reports ~$200 million saved since 2024 across 9 million enrolled lives through 15% cost cap or 3:1 savings guarantee structure. This represents early evidence that managed-access infrastructure can contain costs, though the $200M savings across 9M lives (~$22/member) is modest relative to the 10x PMPM increase that created the fiscal pressure.
+
+
+## Extending Evidence
+
+**Source:** Evernorth EncircleRx operational data
+
+Evernorth EncircleRx manages 9 million enrolled lives with 15% cost cap or 3:1 savings guarantee, saving ~$200 million since 2024. This demonstrates that managed-access infrastructure with behavioral gates and outcomes-based contracting can create fiscal sustainability mechanisms beyond simple formulary exclusion.

domains/health/glp1-persistence-improves-with-specialist-care-supporting-obesity-medicine-infrastructure.md

@@ -11,9 +11,16 @@ sourced_from: health/2025-truveta-ispor-glp1-discontinuation-reasons.md
 scope: correlational
 sourcer: Truveta Research
 supports: ["glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support"]
-related: ["digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring", "glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp1-long-term-persistence-ceiling-14-percent-year-two", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x"]
+related: ["digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring", "glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp1-long-term-persistence-ceiling-14-percent-year-two", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x", "glp1-persistence-improves-with-specialist-care-supporting-obesity-medicine-infrastructure", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap"]
 ---
 
 # Endocrinologists and obesity specialists achieve higher GLP-1 12-week completion rates than primary care providers supporting specialized obesity medicine infrastructure investment
 
 Truveta's real-world analysis found that patients receiving GLP-1 therapy from endocrinologists and obesity specialists demonstrate higher 12-week completion rates compared to those treated by primary care providers. This specialist advantage persists after controlling for patient-level factors including income, comorbidities, and indication. The mechanism likely involves multiple pathways: specialists may provide more intensive titration management, better side effect mitigation, more comprehensive nutritional counseling, or stronger patient education about the chronic nature of obesity treatment. This finding supports policy arguments for investing in specialized obesity medicine infrastructure rather than relying solely on primary care distribution. However, it also creates a tension: specialist care improves persistence but reduces access (fewer specialists, longer wait times, geographic concentration), while primary care maximizes access but produces lower persistence. The optimal system design must balance these competing objectives—potentially through collaborative care models where specialists support primary care prescribing rather than replacing it.
+
+
+## Supporting Evidence
+
+**Source:** Optum Rx Weight Engage, UHC Total Weight Support structure
+
+Optum Rx Weight Engage pairs GLP-1 access with obesity specialist navigation, coaching, and lifestyle programs. UHC Total Weight Support requires coaching engagement as coverage prerequisite. This confirms that payers are operationalizing the specialist-care persistence mechanism through mandatory infrastructure.

inbox/queue/2026-04-28-glp1-managed-access-operating-systems-payer-infrastructure.md

@@ -1,112 +0,0 @@
----
-type: source
-title: "GLP-1 Managed-Access Operating Systems: How Payers Are Building Infrastructure Beyond Formulary"
-author: "on/healthcare tech (strategy analysis)"
-url: https://www.onhealthcare.tech/p/how-commercial-insurers-self-insured
-date: 2026-01-01
-domain: health
-secondary_domains: []
-format: analysis
-status: unprocessed
-priority: high
-tags: [GLP-1, payer, infrastructure, managed-access, value-based-care, employer-benefits, utilization-management]
-intake_tier: research-task
----
-
-## Content
-
-Strategic analysis of how payers, PBMs, and employers are restructuring GLP-1 access as a managed-access operating system rather than a standard formulary decision.
-
-**The core argument:**
-Traditional yes/no formulary structure cannot accommodate GLP-1 economics:
-- Eligible population: 36.2 million commercially insured adults
-- Cost: $1,000-$1,200+/month recurring
-- Multiple indications: obesity, T2D, cardiovascular risk (2024), MASH F2-F3 fibrosis (2025), sleep apnea (December 2024)
-- The decision tree: which populations qualify, under what thresholds, through which channels, with what behavioral gates, at what subsidy levels, with what discontinuation rules
-
-This requires an operating system, not a formulary.
-
-**Payer infrastructure being built (2025-2026):**
-
-Evernorth EncircleRx:
-- Manages 9 million enrolled lives
-- 15% cost cap or 3:1 savings guarantee
-- ~$200 million saved since 2024
-- $200 copay cap on Wegovy and Zepbound added 2025
-
-Optum Rx Weight Engage:
-- Pairs GLP-1 access with obesity specialist navigation, coaching, lifestyle programs
-
-UHC Total Weight Support:
-- Requires coaching engagement (Real Appeal Rx or WeightWatchers) as COVERAGE PREREQUISITE
-- [Note: WeightWatchers bankruptcy creates a gap here — the mandated vendor went bankrupt]
-
-**Manufacturer direct-to-employer channels (early 2026):**
-
-Eli Lilly Employer Connect (March 5, 2026):
-- $449/dose Zepbound direct to employers (vs. $1,000+ retail)
-- 15+ program administrator partnerships: GoodRx, Teladoc, Calibrate, Form Health, Waltz
-- Bypasses PBMs entirely
-
-Novo Nordisk parallel DTE:
-- Waltz Health and 9amHealth partnerships
-- Launched January 1, 2026
-
-**Indication expansion creating complexity:**
-- Wegovy: cardiovascular risk reduction (2024)
-- Wegovy: noncirrhotic MASH with F2-F3 fibrosis (2025)
-- Zepbound: moderate-to-severe obstructive sleep apnea (December 2024)
-Each indication requires distinct medical-necessity criteria and cost-offset narratives.
-
-**The persistence problem (framing the infrastructure need):**
-Meta-regression data:
-- ~50% discontinuation within one year
-- ~60% weight regain within 12 months of cessation
-- 1-in-12 patients remain on therapy at three years (Prime Therapeutics, cited by Mercer)
-These numbers make the ROI case for managed access infrastructure: without behavioral gates, drug-only GLP-1 coverage is cost without durable benefit.
-
-**Infrastructure opportunities identified:**
-- Utilization management infrastructure
-- Outcomes-based contracting frameworks
-- Indication-specific cardiometabolic programs
-- Adherence, tapering, and discontinuation management systems
-- Employer-side financing or subsidy products
-
-**Coverage expansion from search data:**
-- 43% of 5,000+ employee firms cover GLP-1s for weight loss (up from 28% in 2024)
-- 34% now require behavioral participation as coverage condition (up from 10%)
-- State mandates emerging: North Dakota first (January 2025), California/Connecticut/West Virginia introducing similar legislation
-- CMS: Medicare Part D coverage beginning January 2027
-
-## Agent Notes
-
-**Why this matters:** The "managed-access operating system" framing is conceptually important. The previous KB description of GLP-1 economics treated the drug as a standalone product with an adherence problem. This analysis shows that payers are treating the drug + behavioral infrastructure as a SYSTEM — a complex managed product requiring ongoing operational management. This changes the nature of what business opportunities exist.
-
-**What surprised me:** The manufacturer direct-to-employer channels (Lilly Employer Connect, Novo/Waltz/9amHealth) launched in early 2026. This is manufacturers BYPASSING PBMs to sell directly to employers. If successful, this represents a structural shift in who controls GLP-1 access architecture. The PBMs (Evernorth, Optum Rx) are building infrastructure to stay relevant; manufacturers are trying to go around them.
-
-**What I expected but didn't find:** More detail on which employers are using which vendor. UHC requires Real Appeal Rx or WeightWatchers coaching — but WeightWatchers went bankrupt in May 2025 (three months before this analysis). Does UHC now require the post-bankruptcy "clinical-behavioral hybrid" WeightWatchers? This gap in the record is interesting.
-
-**New structural insight — the infrastructure layer is separate from the coaching layer:**
-The previous session identified "behavioral support" as the moat opportunity. This analysis reveals a more complex infrastructure stack:
-1. **Access layer**: PBM formulary, prior auth, utilization management (Evernorth, Optum Rx)
-2. **Behavioral coaching layer**: Omada, Noom, Calibrate, WeightWatchers — where atoms-to-bits moat applies
-3. **Contracting layer**: Outcomes-based contracts, risk-sharing (Evernorth's cost cap)
-4. **Manufacturer direct layer**: Lilly Employer Connect, Novo/Waltz — bypassing traditional channels
-
-Each layer has different moat characteristics. The behavioral coaching layer is where atoms-to-bits applies. The access/contracting layer is where PBM scale applies. The manufacturer direct layer is where brand power applies.
-
-**KB connections:**
-- [[four competing payer-provider models are converging toward value-based care with vertical integration dominant today but aligned partnership potentially more durable]] — the managed-access OS is a new configuration that doesn't fit cleanly into the existing four-model framework
-- [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]] — behavioral gates are a new mechanism for risk alignment at the pharmacy benefit level
-
-**Extraction hints:**
-- CLAIM: "GLP-1 economics require managed-access operating systems beyond standard formulary — payers are building multi-layer access infrastructure covering eligibility, behavioral gates, indication-specific criteria, and discontinuation management" — confidence: likely
-- CLAIM: "Manufacturer direct-to-employer channels (Lilly Employer Connect March 2026, Novo Nordisk January 2026) represent structural challenge to PBM intermediation in GLP-1 access" — confidence: experimental (too new to confirm durability)
-- UPDATE: The "inflationary through 2035" GLP-1 claim is further complicated by manufacturer DTE channels at $449/dose vs. $1,000 retail — pricing compression may be faster than expected
-
-**Context:** on/healthcare.tech is a B2B healthcare strategy newsletter (paywalled). This represents sophisticated market analysis from the payer/employer strategy perspective, not consumer-facing.
-
-## Curator Notes
-PRIMARY CONNECTION: [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]
-WHY ARCHIVED: The "managed-access OS" framing is conceptually new — it positions GLP-1 payer infrastructure as a distinct platform opportunity from behavioral coaching, adding a layer to the claim landscape
-EXTRACTION HINT: Extract the managed-access OS framing as a new claim; separately extract the manufacturer-DTE structural disruption as a second claim — these are two distinct insights from the same source